Innate Pharma : Extension de la collaboration avec Sanofi
>Des paiements pouvant atteindre les 1.3 Md€ - Innate Pharma annonce ce matin la conclusion d’un nouvel accord avec Sanofi visant l’extension de leur collaboration autour des NK cell engagers. A travers cette extension, le géant français obtient une licence exclusive pour 1/ le développement et la commercialisation d’un anticorps multispécifique provenant de la plateforme ANKET ciblant B7H3 et 2/ une option permettant d’ajouter jusqu’à 2 cibles additionnelles provenan...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.